<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04518124</url>
  </required_header>
  <id_info>
    <org_study_id>N19PCA</org_study_id>
    <nct_id>NCT04518124</nct_id>
  </id_info>
  <brief_title>Propranolol in Angiosarcoma</brief_title>
  <official_title>Neoadjuvant Trial on the Efficacy of Propranolol Monotherapy in Cutaneous Angiosarcoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Netherlands Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Anticancer Fund, Belgium</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The Netherlands Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a window opportunity study of propranolol in patients with angiosarcoma. The aim of&#xD;
      this study is to prospectively evaluate the activity of propranolol in the clinical setting&#xD;
      as monotherapy, where the neoadjuvant setting provides a good opportunity to rapidly evaluate&#xD;
      both the clinical response and histological response, without a significant delay in&#xD;
      anti-cancer treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A pilot neoadjuvant window of opportunity study will be performed to explore the activity of&#xD;
      propranolol monotherapy in angiosarcoma. The study consists of a single arm. Propranolol will&#xD;
      be administred as monotherapy in a dose of 40-80 mg 2-3 times a day, if tolerated. When&#xD;
      patients are diagnosed, standard anti-cancer treatment will be scheduled in 6 weeks while&#xD;
      propranolol treatment can start immediately after diagnosis and will be continued until the&#xD;
      day the standard anti-cancer treatment is started. The duration of treatment will therefore&#xD;
      be 3-6 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 27, 2019</start_date>
  <completion_date type="Anticipated">December 27, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 27, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical response</measure>
    <time_frame>From start to end of treatment: 3-6 weeks</time_frame>
    <description>A response is defined as CR, PR, or SD with an improvement in clinical characteristics</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Histological response on propranolol treatment</measure>
    <time_frame>through study completion, an average of 2 years</time_frame>
    <description>The histologic response defined as a decrease of &gt;30% of Ki-67 index between pre- and post-propranolol treatment biopsies.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">14</enrollment>
  <condition>Angiosarcoma</condition>
  <arm_group>
    <arm_group_label>Propranolol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propranolol</intervention_name>
    <description>Propranolol will be administered as monotherapy in a dose of 40-80 mg 2-3 times a day, if tolerated. The study consists of a single arm.</description>
    <arm_group_label>Propranolol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histological proof of angiosarcoma&#xD;
&#xD;
          2. Patients with primary, recurrent and metastasised disease are eligible;&#xD;
&#xD;
          3. Patients with a window of at least 3 weeks before surgery or systemic therapy;&#xD;
&#xD;
          4. Age ≥ 18 years;&#xD;
&#xD;
          5. Able and willing to give written informed consent;&#xD;
&#xD;
          6. WHO performance status of 0, 1 or 2;&#xD;
&#xD;
          7. Evaluable disease according to RECIST 1.1 criteria; radiologic visible disease is not&#xD;
             obligated in patients with cutaneous angiosarcoma&#xD;
&#xD;
          8. Minimal acceptable safety laboratory values&#xD;
&#xD;
          9. ANC of ≥ 1.5 x 109 /L&#xD;
&#xD;
         10. Platelet count of ≥ 100 x 109 /L&#xD;
&#xD;
         11. Hepatic function as defined by serum bilirubin ≤ 1.5 x ULN, ASAT and ALAT ≤ 2.5 x ULN&#xD;
&#xD;
         12. Renal function as defined by serum creatinine ≤ 1.5 x ULN or creatinine clearance ≥ 50&#xD;
             mL/min (by Cockcroft-Gault formula);&#xD;
&#xD;
         13. At least one tumor lesion accessible to safely biopsy per clinical judgement of the&#xD;
             treating physician&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Contraindication for propranolol therapy, like severe hypotension or bradycardia,&#xD;
             sicksinus syndrome, second or third grade heart block, cardiogenic shock, untreated&#xD;
             heart failure, severe peripheral vascular disease asthma or other obstructive lung&#xD;
             diseases, untreated pheochromocytoma, metabolic acidosis, prolonged fasting.&#xD;
&#xD;
          2. Current treatment with β-blockade therapy.&#xD;
&#xD;
          3. Any anticancer treatment within 30 days prior to receiving the first dose of&#xD;
             investigational treatment; with the exception of hormonal therapy for breast cancer.&#xD;
&#xD;
          4. Concurrent treatment with an anticancer therapy: with the exception of hormonal&#xD;
             therapy for breast cancer.&#xD;
&#xD;
          5. Patients with known alcoholism, drug addiction and/or psychiatric of physiological&#xD;
             condition which in the opinion of the investigator would impair study compliance;&#xD;
&#xD;
          6. Evidence of any other disease, neurological or metabolic dysfunction, physical&#xD;
             examination finding or laboratory finding giving reasonable suspicion of a disease or&#xD;
             condition that contraindicates the use of an investigational drug or puts the patient&#xD;
             at high risk for treatment-related complications;&#xD;
&#xD;
          7. Pregnancy;&#xD;
&#xD;
          8. Legal incapacity&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Winan van Houdt, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Netherlands Cancer Institute - Antoni van Leeuwenhoek</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Neeltje Steeghs, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Netherlands Cancer Institute - Antoni van Leeuwenhoek</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alaa Embaby, MD</last_name>
    <phone>+31 (0)20 5129111</phone>
    <email>a.embaby@nki.nl</email>
  </overall_contact>
  <location>
    <facility>
      <name>Netherlands Cancer Institute - Antoni van Leeuwenhoek</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alaa Embaby, MD</last_name>
      <phone>+31 (0)20 512 9111</phone>
      <email>a.embaby@nki.nl</email>
    </contact>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>June 9, 2020</study_first_submitted>
  <study_first_submitted_qc>August 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 19, 2020</study_first_posted>
  <last_update_submitted>November 16, 2020</last_update_submitted>
  <last_update_submitted_qc>November 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Propranolol</keyword>
  <keyword>Angiosarcoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemangiosarcoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propranolol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

